The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Open accessPublished version of a preprint
Abstract
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates MHC I, enriching for durable ICB benefit. In vitro modeling confirms epigenetic recovery of MHC I in SCLC following loss of neuroendocrine differentiation, which tracks with derepression of STING. Transient EZH2 inhibition expands these nonneuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. Consistent with these findings, murine nonneuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. Therapeutically, EZH2 inhibition followed by STING agonism enhances T-cell recognition and rejection of SCLC in mice. Together, these data identify MHC I as a novel biomarker of SCLC immune responsiveness and suggest novel immunotherapeutic approaches to co-opt SCLC's intrinsic immunogenicity. Significance: SCLC is poorly immunogenic, displaying modest ICB responsiveness with rare durable activity. In profiling its plasticity, we uncover intrinsically immunogenic MHC Ihi subpopulations of nonneuroendocrine SCLC associated with durable ICB benefit. We also find that combined EZH2 inhibition and STING agonism uncovers this cell state, priming cells for immune rejection. This article is highlighted in the In This Issue feature, p. 1861
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“recent studies have provided compelling evidence that tumor cell-intrinsic STING activity is also an important contributor34–36.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Scenic: single-cell regulatory network inference and clustering.
Aibar, S., González-Blas, C. B., Moerman, T., Huynh-Thu, V. A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.-C., Geurts, P., Aerts, J., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4463 · Cited by 6,520
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E. M., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Đačić, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,532
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,192
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X. L., Fernandez‐Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,362
Mapping the Mouse Cell Atlas by Microwell-Seq
Han, X., Wang, R., Zhou, Y., Fei, L., Sun, H., Lai, S., Saadatpour, A., Zhou, Z., Chen, H., Ye, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.001 · Cited by 1,597
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E. B., Lehman, J. M., MacPherson, D. P., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,251
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lü, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 988
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.87 · Cited by 900
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900
Self-citationBurr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Identification of human cancers deficient in antigen processing.
Restifo, N. P., Esquivel-Guadarrama, F. R., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., & Bennink, J. R. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.2.265 · Cited by 627
Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels
Shin, Y., Han, S., Jeon, J. S., Yamamoto, K., Zervantonakis, I. K., Sudo, R., Kamm, R. D., & Chung, S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.051 · Cited by 617
Self-citationA Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O. O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 553
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
Self-citationOtt, P. A., Élez, E., Hiret, S., Kim, D., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.006 · Cited by 516
Ireland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., Conley, C. C., Chen, O. S., Guthrie, M. R., Soltero, D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.001 · Cited by 515
Borromeo, M. D., Savage, T. K., Kollipara, R. K., He, M. Y., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 502
Gazdar, A. F., Carney, D. N., Nau, M. M., & Minna, J. D. (1985) · PubMed · Cited by 477
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Self-citationMapping the Mouse Cell Atlas by Microwell-Seq
Han, X., Wang, R., Zhou, Y., Fei, L., Sun, H., Lai, S., Saadatpour, A., Zhou, Z., Chen, H., Ye, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.012 · Cited by 384
Doyle, A., Wj, M., Funa, K., Gazdar, A. F., Carney, D., Martin, S., Linnoila, I. R., Cuttitta, F. F., Mulshine, J. L., & Bunn, P. A. (1985) · The Journal of Experimental Medicine · doi:10.1084/jem.161.5.1135 · Cited by 383
Stewart, C. A., Gay, C. M., Xi, Y., Sivajothi, S. K., Vijayakumar, S., Fujimoto, J., Bolisetty, M. T., Hartsfield, P. M., Balasubramaniyan, V., Chalishazar, M. D., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0020-z · Cited by 377
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Calbó, J., van Montfort, E. H. N., Proost, N., van Drunen, E., Beverloo, H. B., Meuwissen, R. L. J., & Berns, A. J. M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.021 · Cited by 371
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 324
Self-citationGeneration of T-cell receptor retrogenic mice
Holst, J., Szymczak-Workman, A. L., Vignali, K. M., Burton, A. R., Workman, C. J., & Vignali, D. A. A. (2006) · Nature Protocols · doi:10.1038/nprot.2006.61 · Cited by 276
Zhou, L., Mudianto, T., Ma, X., Riley, R., & Uppaluri, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1351 · Cited by 269
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, A. R., Campisi, M., Ivanova, E., Portell, A., Larios, D., Piel, B. P., Mathur, N., Zhou, C., Coakley, R. V., Bartels, A., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00322j · Cited by 265
Self-citationPoirier, J. T., Gardner, E. E., Connis, N., Moreira, A. L., de Stanchina, E., Hann, C. L., & Rudin, C. M. (2015) · Oncogene · doi:10.1038/onc.2015.38 · Cited by 249
Vasculogenic mimicry in small cell lung cancer
Williamson, S. C., Metcalf, R. L., Trapani, F., Mohan, S., Antonello, J., Abbott, B., Leong, H. S., Chester, C., Simms, N., Polański, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13322 · Cited by 246
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99760 · Cited by 244
PD-L1 expression in small cell neuroendocrine carcinomas
Schultheis, A. M., Scheel, A. H., Ozretić, L., George, J., Thomas, R. K., Hagemann, T., Zander, T., Wolf, J., & Buettner, R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.006 · Cited by 237
Wang, S., Tang, J., Sun, T., Zheng, X., Li, J., Sun, H., Zhou, X., Zhou, C., Zhang, H., Cheng, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01571-0 · Cited by 234
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 222
Self-citationCornwell, M., Vangala, M., Taing, L., Herbert, Z. T., Köster, J., Li, B., Sun, H., Li, T., Zhang, J., Qiu, X., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2139-9 · Cited by 207
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.011 · Cited by 197
Self-citationEpigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
Balanis, N. G., Sheu, K. M., Esedebe, F. N., Patel, S. J., Smith, B. A., Park, J. W., Alhani, S., Gomperts, B. N., Huang, J., Witte, O. N., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.005 · Cited by 179
Simpson, K., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., Humphrey, S., Booth, L., Morgan, D., Dynowski, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0046-2 · Cited by 176
Erratum: Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.110 · Cited by 167
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette, M., Marabelle, A., & Houot, R. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.010 · Cited by 152
Cañadas, I., Rojo, F., Taus, Á., Arpí, O., Arumí-Uría, M., Pijuán, L., Menéndez, S., Zazo, S., Dómine, M., Salido, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1330 · Cited by 140
Self-citationErratum: Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.106 · Cited by 139
Oser, M. G., Sabet, A. H., Gao, W., Chakraborty, A. A., Schinzel, A. C., Jennings, R. B., Fonseca, R., Bonal, D. M., Booker, M. A., Flaifel, A., et al. (2019) · Genes & Development · doi:10.1101/gad.328336.119 · Cited by 134
Self-citationPoczobutt, J. M., De, S., Yadav, V. K., Nguyen, T. T., Li, H. Y., Sippel, T. R., Weiser-Evans, M. C. M., & Nemenoff, R. A. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502364 · Cited by 97
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
Self-citationBrazin, K. N., Mallis, R. J., Boeszoermenyi, A., Feng, Y., Yoshizawa, A., Reche, P. A., Kaur, P., Bi, K., Hussey, R. E., Duke‐Cohan, J. S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.007 · Cited by 76
Self-citationAlternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome
Oliveira, C. C., & van Hall, T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00298 · Cited by 72
Pearsall, S. M., Humphrey, S., Revill, M., Morgan, D., Frese, K. K., Galvin, M., Kerr, A. R. W., Carter, M., Priest, L. J. C., Blackhall, F. H., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.008 · Cited by 71
Sato, T., Yoo, S., Kong, R., Fridrikh, M., Sinha, A., Chandramani-Shivalingappa, P., Patel, A., Nagano, O., Masuko, T., Beasley, M. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2132 · Cited by 44
Self-citationFuna, N. S., Gazdar, A. F., Minna, J. D., & Linnoila, R. I. (1986) · PubMed · Cited by 43
Wickström, S. L., Lövgren, T., Volkmar, M., Reinhold, B. B., Duke‐Cohan, J. S., Hartmann, L., Rebmann, J., Müeller, A., Melief, J., Maas, R. R., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02766 · Cited by 32
Self-citation
Cited by
Sorted by citations
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Jaspers, J. E., Khan, J. F., Godfrey, W. D., Lopez, A. V., Ciampricotti, M., Rudin, C. M., & Brentjens, R. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166028 · Cited by 191
H3K27me3 conditions chemotolerance in triple-negative breast cancer
Marsolier, J., Prompsy, P., Durand, A., Lyne, A.-M., Landragin, C., Trouchet, A., Bento, S. T., Eisele, A. S., Foulon, S., Baudre, L., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01047-6 · Cited by 194
Berger, G., Knelson, E. H., Jimenez-Macias, J. L., Nowicki, M. O., Han, S., Panagioti, E., Lizotte, P. H., Adu-Berchie, K., Stafford, A., Dimitrakakis, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111003119 · Cited by 179
Self-citationRadiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Nishiga, Y., Drainas, A. P., Baron, M., Bhattacharya, D., Barkal, A. A., Ahrari, Y., Mancusi, R. A., Ross, J., Takahashi, N., Thomas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00456-0 · Cited by 180
Metadata
- Authors
- Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., Reinhold, B. B., Duke-Cohan, J. S., Poitras, M. J., Taus, L. J., Lizotte, P. H., Portell, A., Quadros, V., Santucci, A. D., Murayama, T., Cañadas, I., Kitajima, S., Akitsu, A., Fridrikh, M., Watanabe, H., Reardon, B., Gokhale, P. C., Paweletz, C. P., Awad, M. M., Van Allen, E. M., Lako, A., Wang, X.-T., Chen, B., Hong, F., Sholl, L. M., Tolstorukov, M. Y., Pfaff, K., Jänne, P. A., Gjini, E., Edwards, R., Rodig, S., Reinherz, E. L., Oser, M. G., & Barbie, D. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Politecnico di Torino (IT)
- Harvard University (US)
- 6Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Fox Chase Cancer Center (US)
- Tisch Cancer Institute (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Bristol-Myers Squibb (United States) (US)
- 14Translational Pathology, Bristol Myers Squibb, Trenton, New Jersey.
- Corresponding author
- Oser, Matthew G.
- Barbie, David A.
- ORCID
- Mahadevan, Navin R.
- Knelson, Erik H.
- Wolff, Jacquelyn O.
- Vajdi, Amir
- Saigí, Maria
- Campisi, Marco
- Hong, Deli
- Thai, Tran C.
- Piel, Brandon
- Han, Saemi
- Duke-Cohan, Jonathan S.
- Taus, Luke J.
- Lizotte, Patrick H.
- Portell, Andrew
- Quadros, Victor
- Santucci, Alison D.
- Murayama, Takahiko
- Cañadas, Israel
- Kitajima, Shunsuke
- Akitsu, Aoi
- Watanabe, Hideo
- Reardon, Brendan
- Gokhale, Prafulla C.
- Paweletz, Cloud P.
- Awad, Mark M.
- Lako, Ana
- Hong, Fangxin
- Sholl, Lynette M.
- Tolstorukov, Michael Y.
- Pfaff, Kathleen
- Gjini, Evisa
- Edwards, Robin
- Rodig, Scott
- Reinherz, Ellis L.
- Oser, Matthew G.
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2021-03-11
- Volume
- 11
- Issue
- 8
- Pages
- 1952-1969
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8338750
- OpenAlex
- W3134054679
- Cited by
- 227
- References
- 69
- Citations by year
- 2026: 47 · 2025: 53 · 2024: 55 · 2023: 35 · 2022: 29 · 2021: 8
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (R01CA190294, T32HL7627-35, T32CA251062, T32 CA009172, 5 P30 CA06516, S10OD018522, S10OD026880)
- NCI NIH (K08CA222657)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- small cell lung cancer, cellular plasticity, MHC class I upregulation, immune checkpoint blockade, EZH2 inhibition, neuroendocrine differentiation, epigenetic reprogramming, antigen presentation, CD8+ T cells, tumor immunogenicity, combination immunotherapy
- MeSH terms
- Cell Plasticity, Animals, Disease Models, Animal, Humans, Lung Neoplasms, Cohort Studies, Mice, Small Cell Lung Carcinoma, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
